The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Official Title: An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer
Study ID: NCT00113607
Brief Summary: The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.
Detailed Description: This is a multicenter, open-label (all people know the identity of the intervention), randomized (study medication is assigned by chance), Phase 3 study comparing the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with advanced ovarian cancer (who were previously treated and for whom first-line platinum-based chemotherapy regimen has failed). Approximately 650 patients will be randomly assigned to 1 of the treatment arms (DOXIL and DOXIL + trabectedin) over 2 years. At the time of randomization, patients will be stratified on the basis of platinum sensitivity of disease (sensitive or resistant) and baseline Eastern Cooperative Oncology Group performance status score (0 to 1 or 2. Safety will be evaluated on the basis of adverse events, clinical laboratory tests, physical examination, vital signs assessment and cardiovascular safety assessment. An interim analysis of overall survival will be performed in conjunction with progression-free survival analysis during the study. Treatment will be continued until disease progression occurred or until patients experienced a confirmed complete response for at least 2 cycles. Continuation of treatment in select individual patients beyond this study end date will be allowed if the investigator determined that the patient is benefiting from treatment, is eligible to receive further therapy, and consents to treatment. If disease progression has not occurred at treatment termination, then disease assessment will continue every 8 weeks until there is evidence of disease progression or death, or until the clinical data cutoff date, or until the start of first subsequent anticancer therapy, whichever is earlier.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
, Mobile, Alabama, United States
, Tucson, Arizona, United States
, Los Angeles, California, United States
, Newport Beach, California, United States
, Orange, California, United States
, Englewood, Colorado, United States
, Stamford, Connecticut, United States
, Tampa, Florida, United States
, Coeur D Alene, Idaho, United States
, Louisville, Kentucky, United States
, New Orleans, Louisiana, United States
, Boston, Massachusetts, United States
, Minneapolis, Minnesota, United States
, Saint Louis, Missouri, United States
, Morristown, New Jersey, United States
, New York, New York, United States
, Charlotte, North Carolina, United States
, Greenville, North Carolina, United States
, Winston Salem, North Carolina, United States
, Cleveland, Ohio, United States
, Toledo, Ohio, United States
, Portland, Oregon, United States
, Pittsburgh, Pennsylvania, United States
, Greenville, South Carolina, United States
, Chattanooga, Tennessee, United States
, Nashville, Tennessee, United States
, Dallas, Texas, United States
, Galveston, Texas, United States
, Buenos Aires, , Argentina
, Mendoza, , Argentina
, Sante Fe, , Argentina
, Adelaide, , Australia
, Bentleigh, , Australia
, Douglas, , Australia
, St Leonards, , Australia
, Toorak Gardens, , Australia
, Edegem, , Belgium
, Hasselt, , Belgium
, Leuven, , Belgium
, Wilrijk, , Belgium
, Barretos, , Brazil
, Belo Horizonte, , Brazil
, Cerqueira Cesar, , Brazil
, Londrina, , Brazil
, Santo Andre, , Brazil
, Sao Paulo, , Brazil
, Calgary, Alberta, Canada
, Edmonton, Alberta, Canada
, Ottawa, Ontario, Canada
, Montreal, Quebec, Canada
, Quebec City, Quebec, Canada
, Reneca, , Chile
, Santiago, , Chile
, Beijing, , China
, Guangzhou, , China
, Hangzhou, , China
, Jinan, , China
, Shanghai, , China
, Chartres, , France
, Paris, , France
, Pierre Benite Cedex, , France
, Düsseldorf, , Germany
, Heidelberg, , Germany
, Jena, , Germany
, Karlsruhe, , Germany
, Mainz, , Germany
, Villingen-Schwenningen, , Germany
, Wilhelmshaven, , Germany
, Chai Wan, , Hong Kong
, Hong Kong, , Hong Kong
, Sha Tin, , Hong Kong
, Seoul, , Korea, Republic of
, Amsterdam, , Netherlands
, Enschede, , Netherlands
, Groningen, , Netherlands
, Maastricht, , Netherlands
, Gdansku, , Poland
, Gliwice, , Poland
, Krakow, , Poland
, Olsztyn, , Poland
, Poznan, , Poland
, Warszawa Poland, , Poland
, Wroclaw, , Poland
, Chelyabinsk, , Russian Federation
, Moscow N/A, , Russian Federation
, Moscow, , Russian Federation
, Obninsk, Kaluga Region, , Russian Federation
, Orenburg, , Russian Federation
, Saint Petersburg, , Russian Federation
, Samara, , Russian Federation
, St. Petersburg, , Russian Federation
, Singapore, , Singapore
, Barcelona, , Spain
, Girona, , Spain
, Guadalajara, , Spain
, L'Hospitalet De Llobregat, , Spain
, Madrid, , Spain
, Maranon, , Spain
, Valencia, , Spain
, Zaragoza, , Spain
, Göteborg, , Sweden
, Umeå, , Sweden
, Uppsala, , Sweden
, Kaohsiung County, , Taiwan
, Taipei, , Taiwan
, Tao-Yuan, , Taiwan
, Birmingham, , United Kingdom
, Edinburgh, , United Kingdom
, Leicester, , United Kingdom
, London, , United Kingdom
, Nottingham, , United Kingdom
, Poole, , United Kingdom
, Sheffield, , United Kingdom
Name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Role: STUDY_DIRECTOR